The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. It will also cover some infectious disease targets.
BioNTech gets the opportunity to tap into the NHS as a source of subjects for its cancer vaccine studies, as well as access to genomics and health data resources, and in return will open an R&D centre in Cambridge, employing more than 70 scientists, as well as an office in London. If successful, the partnership may also lead to manufacturing investments in the UK.
